| Symbol | ELTX |
|---|---|
| Name | ELICIO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE, New York, 11553, United States |
| Telephone | +1 415 655-4899 |
| Fax | — |
| — | |
| Website | https://www.elicio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001601485 |
| Description | Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Companys lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The Company is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The Company provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The Company conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Additional info from NASDAQ: |
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Read moreElicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07083479 | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Panc… | — | Pancreatic Ductal Adenocarcinoma | Available | — | — | ClinicalTrials.gov |
| NCT07399782 | Botulinum Toxin in the Palatopharyngeal Muscle for the Treatment of Obstructive… | Phase2 | Sleep Apnea Syndrome, Obstructive | Not_Yet_Recruiting | 2026-04-05 | 2026-09-01 | ClinicalTrials.gov |
| NCT06408363 | Effectiveness of Sequential Eustachian Tube Maneuvers in Hyperbaric Oxygen Cond… | Na | Barotrauma;Ear | Recruiting | 2023-05-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | Phase1 | Pancreatic Ductal Adenocarcinoma | Active_Not_Recruiting | 2023-04-14 | 2026-11-01 | ClinicalTrials.gov |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcino… | Phase1 | Minimal Residual Disease | Completed | 2021-10-04 | 2024-09-24 | ClinicalTrials.gov |
| NCT00832403 | Gore Tex Implants in the Treatment of Atrophic Rhinitis | — | Atrophic Rhinitis | Suspended | 2006-11-01 | — | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| implants of polytetrafluoroethylene in tha nasal fossa | Other | Preclinical | Atrophic Rhinitis | SUSPENDED | NCT00832403 |
| implants of polytetrafluoroethylene in tha nasal fossa | Other | Preclinical | Atrophic Rhinitis | SUSPENDED | NCT00832403 |
| ELI-002 2P | Other | Phase PHASE1 | Minimal Residual Disease | COMPLETED | NCT04853017 |
| Maneuver group | Other | Approved | Barotrauma;Ear | RECRUITING | NCT06408363 |
| Maneuver group | Other | Approved | Barotrauma;Ear | RECRUITING | NCT06408363 |
| BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE | Other | Phase PHASE2 | Sleep Apnea Syndrome, Obstructive | NOT_YET_RECRUITING | NCT07399782 |
| BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE | Other | Phase PHASE2 | Sleep Apnea Syndrome, Obstructive | NOT_YET_RECRUITING | NCT07399782 |
| BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE | Other | Phase PHASE2 | Sleep Apnea Syndrome, Obstructive | NOT_YET_RECRUITING | NCT07399782 |
| ELI-002 7P | Other | Preclinical | Pancreatic Ductal Adenocarcinoma | AVAILABLE | NCT07083479 |
| ELI-002 7P | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05726864 |